--- title: "NKGen Biotech Announces Major Convertible Financing and Governance Shift" type: "News" locale: "en" url: "https://longbridge.com/en/news/283570068.md" description: "NKGen Biotech has announced a $39.9 million secured convertible loan agreement with AlpineBrook Capital, refinancing existing debts and providing new cash. The loan, convertible at $0.08 per share, is secured by the company's assets and includes provisions for issuing additional shares and board representation for the lender. This financing marks a significant governance shift, as the lender gains influence over strategic decisions and potential dilution for shareholders. NKGen Biotech is focused on immunotherapy treatments and is seeking additional funding to support operations." datetime: "2026-04-21T22:10:32.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/283570068.md) - [en](https://longbridge.com/en/news/283570068.md) - [zh-HK](https://longbridge.com/zh-HK/news/283570068.md) generator: "portal-rs" --- # NKGen Biotech Announces Major Convertible Financing and Governance Shift ### Claim 30% Off TipRanks - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks An update from NKGen Biotech ( (NKGN) ) is now available. On April 15, 2026, NKGen Biotech and its subsidiary entered into a $39.9 million secured convertible loan agreement with AlpineBrook Capital that refinances multiple existing debts and provides $350,000 in new cash, bearing 12% interest and maturing in one year. The loan is convertible into common stock at $0.08 per share, is secured by first-priority liens over most of the company’s personal and intellectual property assets and a pledge of its 65% stake in NKGen Korea, and restricts prepayment and certain corporate actions. As part of the financing, NKGen agreed to issue AlpineBrook up to 11.8 million additional shares as consideration, a warrant to purchase further shares at $0.08, and extensive investor rights including registration rights, the ability to designate up to five board members, broad protective and preemptive rights, and a right of first refusal over any sale of NKGen Korea stock. The board simultaneously amended the bylaws to cap the board size at nine directors, underscoring a material shift in governance and control dynamics as the lender gains significant influence over future financings, strategic decisions, and potential dilution for existing shareholders. **More about NKGen Biotech** NKGen Biotech, Inc. is a Delaware-based biotechnology company focused on developing immunotherapy treatments, with operations that include a majority stake in NKGen Biotech Korea Co., Ltd. The company currently has a limited cash balance and is actively seeking additional funding to support its business operations and working capital needs. **Average Trading Volume:** 4,743 **Technical Sentiment Signal:** Sell **Current Market Cap:** $7.84M Find detailed analytics on NKGN stock on TipRanks’ Stock Analysis page. ### Related Stocks - [NKGN.US](https://longbridge.com/en/quote/NKGN.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [IHE.US](https://longbridge.com/en/quote/IHE.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [XLV.US](https://longbridge.com/en/quote/XLV.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [VHT.US](https://longbridge.com/en/quote/VHT.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [NKGNW.US](https://longbridge.com/en/quote/NKGNW.US.md) ## Related News & Research - [LIVE MARKETS-BofA clients flock to tech stocks](https://longbridge.com/en/news/296383193.md) - [NKGen Biotech Amends $5 Million BDW Loan, Pledging Real Estate as First-Lien Collateral](https://longbridge.com/en/news/293074756.md) - [SBIO: U.S. Programmatic and EMEA drove 49% of Q2 sales, with margins rising to 61% and profitability expected in H2 2026](https://longbridge.com/en/news/296517769.md) - [Guotai Asset Management sees liquidity boost driving China biotech, innovation drug shares higher](https://longbridge.com/en/news/296448906.md) - [Moderna surges on trial win for cancer shot; William Blair upgrades](https://longbridge.com/en/news/296370751.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**